<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270490</url>
  </required_header>
  <id_info>
    <org_study_id>Interferon-gamma 001</org_study_id>
    <secondary_id>2009-014600-66</secondary_id>
    <secondary_id>NL28823.091.10</secondary_id>
    <nct_id>NCT01270490</nct_id>
  </id_info>
  <brief_title>Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia</brief_title>
  <official_title>A Multicentre, Prospective, Randomized Open-label Pilot Study to Assess the Feasibility and Preliminary Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility and preliminary efficacy of
      interferon-gamma in combination with anidulafungin for the treatment of candidemia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the time to negative blood cultures</measure>
    <time_frame>at fixed time points during follow up (at least until 8 weeks after end of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>until 8 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to death</measure>
    <time_frame>Until 8 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>outcome of fungal infection</measure>
    <time_frame>Until 8 weeks after end of treatment</time_frame>
    <description>resolution at week 2 and 8 after end of treatment, patient status at end of therapy, microbiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of antifungal therapy</measure>
    <time_frame>Until end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>Until end of hospitilization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological parameters</measure>
    <time_frame>Until 8 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability and safety</measure>
    <time_frame>until 8 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Candidemia</condition>
  <arm_group>
    <arm_group_label>Interferon-gamma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No adjunctive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-gamma, Recombinant</intervention_name>
    <description>Interferon 50 mcg/m2 to be administered three times per week during two weeks</description>
    <arm_group_label>Interferon-gamma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females (who must agree to use barrier methods of contraception
             during the study therapy period, women of childbearing age must have a negative urine
             pregnancy or serum test at baseline).

          -  Subjects who are 18 years of age or older

          -  Subjects with at least one positive blood culture isolation of Candida species from a
             specimen drawn within 96 hours prior to study entry.

          -  Subjects who have clinical evidence of infection AT SOME TIME WITHIN 96 HOURS PRIOR TO
             ENROLLMENT, including AT LEAST ONE of the following:

               -  Temperature &gt;37.8 ˚C on 2 occasions at least 4 hours apart or one measurement &gt;
                  38.2 ˚C

               -  Systolic blood pressure &lt;90 or a &gt;30 mmHg decrease in systolic BP from the
                  subject's normal baseline.

               -  Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site
                  infected with Candida (eg, joint, skin, eye, bone, esophagus)

               -  Radiologic findings of invasive candidiasis

          -  Subject or their legal representative must sign a written informed consent form.

        Exclusion Criteria:

          -  Subjects with a history of allergy or intolerance to echinocandins or IFNgamma

          -  Subjects with a history of documented epileptic seizures

          -  Subjects with severe renal impairment (creatinine clearance less than 30/mL/min)

          -  Subjects with severe liver failure (impaired synthesis of proteins such as coagulation
             factors manifested by increased prothrombin time)

          -  Subjects with an absolute neutrophil count of less than 500/mm3 at study entry

          -  Women who are pregnant or lactating

          -  Subjects who are unlikely to survive more than 24 hours

          -  Subjects who have failed previous systemic antifungal therapy for the Candida spp.
             infection which is being studied.

          -  Subjects who have received more than 48 hours of systemic antifungal therapy for the
             current episode, within 96 hours prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihai Netea, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corine Delsing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corine Delsing, MD</last_name>
    <phone>+31-24-3618819</phone>
    <email>C.Delsing@AIG.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihai Netea, MD. PhD</last_name>
    <phone>+31-24-3618819</phone>
    <email>M.Netea@AIG.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corine Delsing, MD</last_name>
      <phone>+31-24-3618819</phone>
      <email>C.Delsing@aig.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Corine Delsing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Bleeker-Rovers, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihai Netea, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bart Jan Kullberg, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Corine Delsing</investigator_full_name>
    <investigator_title>Drs</investigator_title>
  </responsible_party>
  <keyword>candidemia</keyword>
  <keyword>candida sepsis</keyword>
  <keyword>invasive fungal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

